AMRS · Amyris, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | $51.08M | - | $65.82M | $55.93M | $48.99M | - | $40.25M | $30.42M | $22.66M | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $26.77M | - | $28.78M | $26.11M | $26.36M | - | $23.82M | $22.42M | $23.33M | - |
| SG&A | $95.87M | - | $124.71M | $126.59M | $106.92M | - | $70.64M | $54.34M | $37.92M | - |
| Total Operating Expenses | $241.61M | - | $219.31M | $208.63M | $182.27M | - | $134.71M | $107.19M | $83.91M | - |
| D&A | $4.53M | - | $3.19M | $2.59M | $2.40M | - | $2.23M | $2.19M | $2.11M | - |
| Operating Income | ($185.53M) | - | ($148.18M) | ($143.42M) | ($124.56M) | - | ($86.84M) | ($54.87M) | $92.95M | - |
| Interest Expense | $12.98M | - | $6.29M | $5.30M | $5.26M | - | $4.32M | $4.72M | $5.81M | - |
| Income Tax | ($860.0K) | - | $152.0K | ($685.0K) | ($820.0K) | - | $58.0K | $57.0K | $55.0K | - |
| Net Income | ($193.34M) | - | ($161.40M) | ($110.01M) | ($107.31M) | - | ($32.94M) | $15.38M | ($291.25M) | - |
| EPS - Basic | ($0.53) | - | ($0.50) | ($0.34) | ($0.34) | - | ($0.11) | $0.05 | ($0.56) | - |
| EPS - Diluted | ($0.53) | - | ($0.50) | ($0.44) | ($0.37) | - | ($0.27) | ($0.56) | ($0.56) | - |
Balance Sheet
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $11.24M | $64.44M | $18.49M | $99.82M | $287.89M | $483.46M | $114.89M | $214.42M | $143.82M | $30.15M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | $109.02M | $111.88M | $129.33M | $99.19M | $82.30M | $75.07M | $72.06M | $54.26M | $47.64M | $42.86M |
| Accounts Payable | $200.07M | $190.49M | $133.82M | $102.96M | $88.29M | $79.67M | $80.64M | $48.61M | $44.15M | $41.05M |
| Current Assets | $243.66M | $306.36M | $272.48M | $310.11M | $470.94M | $639.21M | $278.06M | $349.21M | $252.22M | $146.56M |
| Total Assets | $679.68M | $824.93M | $754.06M | $789.44M | $898.45M | $954.30M | $542.31M | $445.82M | $326.59M | $222.81M |
| Current Liabilities | $470.79M | $387.15M | $309.26M | $187.07M | $266.22M | $269.81M | $460.03M | $94.84M | $147.11M | $163.05M |
| Long-term Debt | $675.86M | $674.89M | $673.93M | $672.97M | $672.00M | $309.06M | $12.10M | $13.84M | $13.87M | $26.17M |
| Total Liabilities | $1.33B | $1.29B | $1.16B | $1.03B | $1.02B | $675.09M | $595.63M | $528.33M | $636.73M | $389.86M |
| Stockholders' Equity | ($664.36M) | ($488.69M) | ($427.58M) | ($272.99M) | ($158.79M) | $246.44M | ($89.17M) | ($122.07M) | ($321.12M) | ($176.82M) |
| Retained Earnings | ($3.07B) | ($2.88B) | ($2.73B) | ($2.57B) | ($2.46B) | ($2.36B) | ($2.40B) | ($2.36B) | ($2.38B) | ($2.09B) |
Cash Flow
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($90.00M) | - | - | - | ($152.44M) | - | - | - | $108.65M | - |
| Investing Cash Flow | ($4.82M) | - | - | - | ($47.29M) | - | - | - | ($2.49M) | - |
| Financing Cash Flow | $41.61M | - | - | - | $3.96M | - | - | - | $7.53M | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | 0.4% | - | - |
| Return on assets | -28.4% | - | -21.4% | -13.9% | -11.9% | - | -6.1% | 3.5% | -89.2% | - |
| Return on equity | 29.1% | - | 37.7% | 40.3% | 67.6% | - | 36.9% | -12.6% | 90.7% | - |
| Return on invested capital | -1275.4% | - | -47.5% | -28.3% | -19.2% | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.52 | 0.79 | 0.88 | 1.66 | 1.77 | 2.37 | 0.60 | 3.68 | 1.71 | 0.90 |
| Quick ratio | 0.29 | 0.50 | 0.46 | 1.13 | 1.46 | 2.09 | 0.45 | 3.11 | 1.39 | 0.64 |
| Cash ratio | 0.02 | 0.17 | 0.06 | 0.53 | 1.08 | 1.79 | 0.25 | 2.26 | 0.98 | 0.18 |
| Leverage | ||||||||||
| Debt / Equity | -1.02 | -1.38 | -1.58 | -2.47 | -4.23 | 1.25 | -0.14 | -0.11 | -0.04 | -0.15 |
| Debt / Assets | 0.99 | 0.82 | 0.89 | 0.85 | 0.75 | 0.32 | 0.02 | 0.03 | 0.04 | 0.12 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | 0.15 | - |
| Interest coverage | -14.3x | - | -23.6x | -27.0x | -23.7x | - | -20.1x | -11.6x | 16.0x | - |
| Equity multiplier | -1.02 | -1.69 | -1.76 | -2.89 | -5.66 | 3.87 | -6.08 | -3.65 | -1.02 | -1.26 |
| Liabilities / Assets | 1.95 | 1.57 | 1.54 | 1.31 | 1.14 | 0.71 | 1.10 | 1.19 | 1.95 | 1.75 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | 0.47 | - | 0.51 | 0.56 | 0.60 | - | 0.56 | 0.56 | 0.48 | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | 779d | - | 717d | 647d | 613d | - | 653d | 651d | 767d | - |
| Days payable outstanding | 1430d | - | 742d | 672d | 658d | - | 731d | 583d | 711d | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -48.9% | - | -70.6% | -161.4% | - | - | -80.6% | -35.3% | - | - |
| Net income growth (YoY) | -80.2% | - | -389.9% | - | 63.2% | - | -42.3% | - | -231.6% | - |
| EPS growth (YoY) | -43.2% | - | -85.2% | 21.4% | 33.9% | - | 34.1% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -318.4% | - | -379.5% | -123.6% | 50.6% | - | -1.2% | -81.2% | -76.7% | 30.9% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$179.77M totalLicenses And Royalties$149.61M · 83.2%
Renewable Products$19.16M · 10.7%
Grants And Collaborations$6.00M · 3.3%
License$5.00M · 2.8%
Peer comparison
Same SIC group: Industrial Organic Chemicals
Comparing AMYRIS against the 5 most active filers in the same SIC group.